CASP3 and neoplasm: Interestingly, only ex vivo cell treatment conditions that allow the release of DAMPs and moderate cleavage of caspase-3 (i.e., cetuximab and/or cisplatin at the IC50) appear to be able to elicit an anti-tumor immune response in immunocompetent animals.